# Uitgebreide vasodilatatie en QoL bij acuut HF: substudie

*geplaatst 2021-10-01 · Hartfalen · ESC heart failure · doi 10.1002/ehf2.13543 · https://hartvaat.nl/2021/10/01/uitgebreide-vasodilatatie-en-qol-bij-acuut-hf-substudie/*

QoL-substudie van de uitgebreide vasodilatiestrategie versus standaardzorg bij acuut hartfalen.

## English: Effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life among patients with acute heart failure.

This quality-of-life substudy showed that a comprehensive vasodilation strategy versus usual care in acute heart failure does not improve long-term health-related quality of life, consistent with the neutral primary endpoint.

## Abstract (original, from the publication)

AIMS: We aimed to assess the long-term effect of a strategy of comprehensive vasodilation versus usual care on health-related quality of life (HRQL) among patients with acute heart failure (AHF). METHODS AND RESULTS: Health-related quality of life was prospectively assessed by the generic 3-levelled EQ-5D and the disease-specific Kansas City Cardiomyopathy Questionnaire (KCCQ) among adult AHF patients enrolled in an international, multicentre, randomised, open-label blinded-end-point trial of a strategy that emphasized early intensive and sustained vasodilation using maximally tolerated doses of established oral and transdermal vasodilators according to systolic blood pressure. Changes in EQ-5D and KCCQ from admission to 180 day follow-up were individually compared between the intensive vasodilatation and the usual care group. Among 666 patients eligible for 180 day follow-up, 284 (43%, median age 79 years, 35% women) and 198 (30%, median age 77 years, 35% women) had completed the EQ-5D and KCCQ at baseline and follow-up, respectively. There was a significant improvement in HRQL as quantified by both, EQ-5D and KCCQ, from hospitalization to 180 day follow-up, with no significant differences in the change of HRQL between both treatment strategies. For instance, 39 (26%) versus 33 (25%) patients had an improvement by at least one level in at least two categories in the EQ-5D. Median increase in KCCQ overall summary score (KCCQ-OSS) was 17.6 (IQR 2.0-42.6) in the intervention group versus 18.5 (IQR 3.9-39.3) in the usual care group (P < 0.001 vs. baseline, P = 0.945 between groups). CONCLUSIONS: Among patients with AHF, long-term HRQL quantified by EQ-5D and KCCQ improved substantially, with overall no significant differences between a strategy of comprehensive vasodilation versus usual care.

Auteurs: Maria Belkin, Desiree Wussler, Danielle Menosi Gualandro, Samyut Shrestha, Ivo Strebel, Assen Goudev, Micha T Maeder, Joan Walter, Dayana Flores, Nikola Kozhuharov, Pedro Lopez-Ayala, Isabelle Danier, Mucio Tavares de Oliveira Junior, Richard Kobza, Hans Rickli, Tobias Breidthardt, Paul Erne, Thomas Münzel, Christian Mueller

---
Bron: ESC heart failure, https://doi.org/10.1002/ehf2.13543. Bijgewerkt 2026-07-03T13:28:33Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.